Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350530
Max Phase: Preclinical
Molecular Formula: C28H48IN8O16P3
Molecular Weight: 972.56
Molecule Type: Small molecule
Associated Items:
ID: ALA3350530
Max Phase: Preclinical
Molecular Formula: C28H48IN8O16P3
Molecular Weight: 972.56
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(CCCCN(C)C(=O)CCCCNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O)C(=O)CCCCNC(=O)CI
Standard InChI: InChI=1S/C28H48IN8O16P3/c1-35(21(39)9-3-5-11-30-20(38)15-29)13-7-8-14-36(2)22(40)10-4-6-12-31-26-23-27(33-17-32-26)37(18-34-23)28-25(42)24(41)19(51-28)16-50-55(46,47)53-56(48,49)52-54(43,44)45/h17-19,24-25,28,41-42H,3-16H2,1-2H3,(H,30,38)(H,46,47)(H,48,49)(H,31,32,33)(H2,43,44,45)/t19-,24-,25-,28-/m1/s1
Standard InChI Key: DFCZPRZVCJOAMC-BESFBVRISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 972.56 | Molecular Weight (Monoisotopic): 972.1446 | AlogP: 0.79 | #Rotatable Bonds: 25 |
Polar Surface Area: 334.86 | Molecular Species: ACID | HBA: 17 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 24 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.90 | CX Basic pKa: 4.74 | CX LogP: -4.31 | CX LogD: -9.45 |
Aromatic Rings: 2 | Heavy Atoms: 56 | QED Weighted: 0.03 | Np Likeness Score: 0.28 |
1. Hampton A, Patel AD, Chawla RR, Kappler F, Hai TT.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases., 25 (4): [PMID:7040662] [10.1021/jm00346a011] |
Source(1):